Aandelen in “Biotechnologie”

Aandeel Datum Koers Evolutie
vlag Quince Therapeutics Inc 20/05 0,900 USD
-0,57% 		-0,57%

Nieuws over “Biotechnologie”

07:00 · Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer · Persbericht

07:00 · Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer · Persbericht

20/05 · Insmed Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 ARISE Study Of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with NTM Lung Disease Caused by MAC at American Thoracic Society 2024 International Conference Plenary Session · Persbericht

20/05 · Anna Richo joins Illumina's Board of Directors · Persbericht

20/05 · Soligenix Encourages Stockholders to Vote Prior to Annual Meeting · Persbericht

20/05 · Compugen Reports First Quarter 2024 Results · Persbericht

20/05 · PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluation · Persbericht

20/05 · BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn · Persbericht

20/05 · Pharming Group to participate in May investor conference · Persbericht

19/05 · NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE® TO HELP PATIENTS LIVING WITH COPD · Persbericht

17/05 · DBV Technologies Announces Plan to Implement ADS Ratio Change · Persbericht

17/05 · Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules · Persbericht

17/05 · FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER · Persbericht

16/05 · BLUE Investors Have Opportunity to Lead bluebird bio, Inc. Securities Fraud Lawsuit · Persbericht

16/05 · Monthly information on share capital and company voting rights · Persbericht

16/05 · DBV Technologies Announces Results of its 2024 Combined General Meeting · Persbericht

16/05 · Voting Rights and Shares Capital of the Company · Persbericht

16/05 · Galapagos creates new subscription right plans · Persbericht

16/05 · Galapagos creëert nieuwe inschrijvingsrechtenplannen · Persbericht

16/05 · Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH · Persbericht

16/05 · Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC · Persbericht

Mijn selecties